Mayo Clinic College of Medicine and Science
Rochester, MN, United States
Eric L. Matteson, M.D., M.P.H., FACP, MACR, is emeritus John F. Finn Professor of Medicine and Emeritus Chair, Division of Rheumatology at Mayo Clinic, Rochester, Minnesota, U.S.A., with joint appointment in the Division of Epidemiology in the Department of Health Sciences Research.
Dr. Matteson is a native of Nebraska, and received his B.A. degree from the University of Nebraska. He received the M.D. from the Friedrich-Alexander University, Erlangen-Nürnberg. Subsequently, he completed residency in internal medicine in the Michigan State University system and a fellowship at the University of Michigan and Mayo Clinic, and received his M.P.H. in Epidemiology from the University of North Carolina, Chapel Hill.
Dr. Matteson’s clinical and research interests are in the fields of vasculitis and inflammatory arthritis, and medical history. He has authored/coauthored over 500 original scientific publications and over 60 book chapters and several books on these topics. His research agenda has included investigation into the epidemiology of these diseases and their clinical disease expression and impact on patients who suffer from them, and clinical trials of novel agents. These studies have included epidemiology, healthcare utilization and mortality of rheumatoid arthritis, vasculitis, polymyalgia rheumatica, Sjögren’s syndrome, gout, sarcoidosis and other diseases. A major focus of the research has been clinical and translational work in rheumatoid lung disease.
Friday, October 24, 2025
8:00 AM – 9:00 AM Central Time
Disclosure(s): Amgen Inc: DSMB for Amgen Clinical trial (Terminated, December 20, 2024); Crystalys Therapeutics Inc: DSMB for Crystalys Clinical trial (Ongoing); Horizon Therapeutics: DSMB for Horizon Clinical trial (Terminated, December 20, 2024)
Friday, October 24, 2025
8:45 AM – 9:00 AM Central Time
Disclosure(s): Amgen Inc: DSMB for Amgen Clinical trial (Terminated, December 20, 2024); Crystalys Therapeutics Inc: DSMB for Crystalys Clinical trial (Ongoing); Horizon Therapeutics: DSMB for Horizon Clinical trial (Terminated, December 20, 2024)
Introduction to Session and Speakers
Friday, October 24, 2025
2:05 PM – 2:10 PM Central Time
Disclosure(s): Amgen Inc: DSMB for Amgen Clinical trial (Terminated, December 20, 2024); Crystalys Therapeutics Inc: DSMB for Crystalys Clinical trial (Ongoing); Horizon Therapeutics: DSMB for Horizon Clinical trial (Terminated, December 20, 2024)
Global Differences in Disease Management Guidelines (LARS Session)
Friday, October 24, 2025
2:05 PM – 4:00 PM Central Time
Disclosure(s): Amgen Inc: DSMB for Amgen Clinical trial (Terminated, December 20, 2024); Crystalys Therapeutics Inc: DSMB for Crystalys Clinical trial (Ongoing); Horizon Therapeutics: DSMB for Horizon Clinical trial (Terminated, December 20, 2024)
Friday, October 24, 2025
2:50 PM – 3:00 PM Central Time
Disclosure(s): Amgen Inc: DSMB for Amgen Clinical trial (Terminated, December 20, 2024); Crystalys Therapeutics Inc: DSMB for Crystalys Clinical trial (Ongoing); Horizon Therapeutics: DSMB for Horizon Clinical trial (Terminated, December 20, 2024)
Friday, October 24, 2025
3:50 PM – 4:00 PM Central Time
Disclosure(s): Amgen Inc: DSMB for Amgen Clinical trial (Terminated, December 20, 2024); Crystalys Therapeutics Inc: DSMB for Crystalys Clinical trial (Ongoing); Horizon Therapeutics: DSMB for Horizon Clinical trial (Terminated, December 20, 2024)
